Large-scale clinical trial launched in England to detect cancer early via blood tests

A significant large-scale clinical trial known as STRIDE-RCT has been launched in England to evaluate whether simple blood tests, supported by artificial intelligence and protein analysis, can improve the early diagnosis of various cancers. Developed by the University of Birmingham, these diagnostic tests analyze blood samples to detect signs of cancer and estimate the primary site of the disease, aiming to facilitate faster patient referral for treatment.

The study involves over 20,000 patients aged 45 and older, recruited from 200 general practice clinics across the National Health Service (NHS). The trial focuses on 13 categories of cancer, including those of the bowel, pancreas, stomach, liver, ovaries, prostate, kidneys, and bladder. These types of cancer are often diagnosed at late stages, contributing to the high mortality rates observed in Britain compared to other OECD countries.

British Health Secretary Yvette Cooper emphasized that early detection significantly enhances the probability of successful treatment outcomes. The research specifically targets patients presenting with persistent symptoms such as abdominal pain, discomfort, or bloating to assess the efficacy of integrating these AI-driven tools into primary care settings.